Phase I Study of Pazopanib in Combination With Weekly Paclitaxel and Carboplatin to Assess the Safety and Tolerability in Patients With Advanced Solid Tumors
Active, no longer recruiting
Phase of Trial: Phase I
Latest Information Update: 31 Jan 2017
At a glance
- Drugs Pazopanib (Primary) ; Carboplatin; Paclitaxel
- Indications Breast cancer
- Focus Adverse reactions
- 20 Jan 2017 Planned End Date changed from 1 Jun 2017 to 1 Jun 2018.
- 20 Jan 2017 Planned primary completion date changed from 1 Jun 2017 to 1 Jun 2018.
- 13 Jul 2016 Status changed from suspended to active, no longer recruiting.